Close
Back to LYRA Stock Lookup

(LYRA) – PRNewswire

Sep 13, 2022 04:01 PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 13, 2022 07:00 AM Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study
Sep 10, 2022 08:00 AM LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting
Sep 8, 2022 07:00 AM Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
Sep 6, 2022 07:00 AM Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022
Aug 29, 2022 07:00 AM Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting
Aug 9, 2022 07:00 AM Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 5, 2022 07:00 AM Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer
Jul 5, 2022 07:00 AM Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022
Jun 17, 2022 04:01 PM Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 26, 2022 07:00 AM Lyra Therapeutics to Present at Upcoming Investor Conferences
May 10, 2022 07:00 AM Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022 07:00 AM Lyra Therapeutics to Present at Upcoming Investor Conferences
Apr 29, 2022 09:07 AM Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022
Apr 25, 2022 07:00 AM Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
Apr 21, 2022 07:00 AM Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
Apr 13, 2022 07:00 AM Lyra Therapeutics Announces Closing of $100.5 Million Private Placement
Apr 8, 2022 07:34 AM Lyra Therapeutics Announces $100.5 Million Private Placement
Mar 9, 2022 07:00 AM Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 7, 2022 07:00 AM Lyra Therapeutics Appoints Jim Tobin to Board of Directors
Feb 28, 2022 07:00 AM Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
Feb 17, 2022 07:00 AM Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman
Jan 24, 2022 07:00 AM Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients
Nov 11, 2021 07:00 AM Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
Nov 9, 2021 04:05 PM Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 2, 2021 07:00 AM Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9
Oct 19, 2021 07:00 AM Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts
Oct 4, 2021 07:00 AM Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Soci

Back to LYRA Stock Lookup